211 related articles for article (PubMed ID: 10870093)
21. Determination of Olanzapine in rat brain using liquid chromatography with coulometric detection and a rapid solid-phase extraction procedure.
Saracino MA; Gandolfi O; Dall'olio R; Albers L; Kenndler E; Raggi MA
J Chromatogr A; 2006 Jul; 1122(1-2):21-7. PubMed ID: 16678187
[TBL] [Abstract][Full Text] [Related]
22. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
Macias WL; Bergstrom RF; Cerimele BJ; Kassahun K; Tatum DE; Callaghan JT
Pharmacotherapy; 1998; 18(6):1237-48. PubMed ID: 9855322
[TBL] [Abstract][Full Text] [Related]
23. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.
Aravagiri M; Ames D; Wirshing WC; Marder SR
Ther Drug Monit; 1997 Jun; 19(3):307-13. PubMed ID: 9200772
[TBL] [Abstract][Full Text] [Related]
24. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
25. Comparative Pharmacokinetics of Nimodipine in Rat Plasma and Tissues Following Intraocular, Intragastric, and Intravenous Administration.
Li F; Fei Q; Mao D; Si Q; Dai M; Ma Q; Zhang H; Bai L; He N
AAPS PharmSciTech; 2020 Aug; 21(6):234. PubMed ID: 32794077
[TBL] [Abstract][Full Text] [Related]
26. Plasma pharmacokinetics and tissue distribution of [6]-gingerol in rats.
Jiang SZ; Wang NS; Mi SQ
Biopharm Drug Dispos; 2008 Dec; 29(9):529-37. PubMed ID: 19051331
[TBL] [Abstract][Full Text] [Related]
27. Behavioral assessment of atypical antipsychotics in rats: studies of the effects of olanzapine (Zyprexa).
Trevitt JT; Carlson BB; Salamone JD
Psychopharmacology (Berl); 1999 Aug; 145(3):309-16. PubMed ID: 10494580
[TBL] [Abstract][Full Text] [Related]
28. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K
Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma.
Steinke W; Ahr HJ; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):939-48. PubMed ID: 9296280
[TBL] [Abstract][Full Text] [Related]
30. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
[TBL] [Abstract][Full Text] [Related]
31. Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate.
Jardemark KE; Liang X; Arvanov V; Wang RY
Neuroscience; 2000; 100(1):1-9. PubMed ID: 10996453
[TBL] [Abstract][Full Text] [Related]
32. Disposition, oral bioavailability, and tissue distribution of zearalenone in rats at various dose levels.
Shin BS; Hong SH; Bulitta JB; Hwang SW; Kim HJ; Lee JB; Yang SD; Kim JE; Yoon HS; Kim DJ; Yoo SD
J Toxicol Environ Health A; 2009; 72(21-22):1406-11. PubMed ID: 20077212
[TBL] [Abstract][Full Text] [Related]
33. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
[TBL] [Abstract][Full Text] [Related]
34. [Monitoring of serum olanzapine during antipsychotic treatment].
Linnet K; Olesen OV
Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.
Li XM; Perry KW; Wong DT; Bymaster FP
Psychopharmacology (Berl); 1998 Mar; 136(2):153-61. PubMed ID: 9551772
[TBL] [Abstract][Full Text] [Related]
36. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine.
Boulton DW; Markowitz JS; DeVane CL
J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(2):319-23. PubMed ID: 11499485
[TBL] [Abstract][Full Text] [Related]
37. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.
Sunkara G; Ayalasomayajula SP; Rao CS; Vennerstrom JL; DeRuiter J; Kompella UB
J Pharm Pharmacol; 2004 Mar; 56(3):351-8. PubMed ID: 15025860
[TBL] [Abstract][Full Text] [Related]
38. Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain.
Guiso G; Caccia S
J Pharm Pharmacol; 2001 Mar; 53(3):317-21. PubMed ID: 11291746
[TBL] [Abstract][Full Text] [Related]
39. Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats.
Liu X; Deng C; Cao S; Gong J; Wang BC; Hu CH
Life Sci; 2015 May; 128():72-8. PubMed ID: 25744410
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of heptastigmine in rats.
Segre G; Cerretani D; Baldi A; Urso R
Pharmacol Res; 1992; 25(2):139-46. PubMed ID: 1635892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
